Immunocore Holdings (IMCR) Income from Continuing Operations (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly Income from Continuing Operations of 12971000.0 for Q1 2026, up 160.25% year-on-year from 4984000.0 in Q1 2025, and up 143.15% on a QoQ basis from 30060000.0 in Q4 2025.
Immunocore Holdings (IMCR) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported Income from Continuing Operations for 6 consecutive years, with 12971000.0 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations rose 160.25% year-over-year to 12971000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 27585000.0 (down 27.23% YoY) and the FY2025 annual result came in at 35514000.0, up 30.48% from the prior year.
- Income from Continuing Operations improved to 12971000.0 in Q1 2026 per IMCR's latest filing, from 30060000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for IMCR reached as high as 12971000.0 in Q1 2026 and fell as low as 30060000.0 in Q4 2025.
- A 5-year average of 10741136.15 and a median of 14622719.55 in 2023 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 864.24% — and 2025, when it plunged 102.24%.
- Year by year, Income from Continuing Operations stood at 29872138.48 in 2022, then surged by 33.95% to 19730000.0 in 2023, then slipped by 20.48% to 23771000.0 in 2024, then dropped by 26.46% to 30060000.0 in 2025, then jumped by 143.15% to 12971000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 12971000.0, 30060000.0, and 196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Immunocore Holdings | 1.80 Bn | 957.43 Mn | 106.24 Mn | 12.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -11.63 Mn |
| Mar 31, 2024 | -24.48 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -29.87 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -19.69 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |